NNC0487-0111 B 10141 is a medication that contains the active ingredient zenagamtide. It is given as a small amount injected under the skin using a pre‑filled pen. In the study, it is taken once a week and is added to the usual heart medicines that participants are already taking. The goal is to see if it can lower the chance of serious heart problems such as heart attacks or strokes.

NNC0487-0111 B 10142 is a formulation of zenagamtide provided in a solution for injection. Participants receive it subcutaneously (under the skin) with a pre‑filled pen, once each week, alongside their regular cardiovascular treatments. The study is testing whether this drug can reduce the risk of major cardiovascular events in people who have existing artery disease and are overweight or obese.

NNC0487-0111 B 10143 is a subcutaneous injection of zenagamtide packaged in a ready‑to‑use pen. It is administered weekly in addition to the participant’s standard heart‑health medicines. Researchers are looking to determine if it helps prevent heart attacks, strokes, or other serious cardiovascular complications.

NNC0487-0111 B 10144 delivers zenagamtide as a solution for injection that is given under the skin using a pre‑filled pen. The drug is taken once a week together with the usual care for cardiovascular disease, and the trial aims to see if it can lower the risk of major adverse cardiovascular events.

NNC0487-0111 B 10145 is a weekly subcutaneous injection of zenagamtide supplied in a pre‑filled pen. Participants continue their regular heart medications while receiving this study drug, which is being evaluated for its ability to reduce serious heart‑related outcomes in people with established artery disease and excess weight.

NNC0487-0111 B 10146 is a zenagamtide solution designed for injection under the skin, administered with a pre‑filled pen once a week. It is added to participants’ standard cardiovascular treatments, and the trial is testing whether it can decrease the likelihood of major cardiovascular events such as heart attacks or strokes.

The trial also involves participants continuing their usual cardiovascular care, often called “standard of care.” This includes the medicines and lifestyle measures they normally take to manage heart disease, such as blood pressure pills, cholesterol‑lowering drugs, and diet or exercise recommendations. The study adds zenagamtide to this existing treatment plan to see if the combination provides extra protection against heart problems.

Atherosclerotic cardiovascular disease – A build‑up of fatty deposits called plaque inside the walls of arteries that supply the heart and brain. Over time the plaque can harden and narrow the arteries, reducing blood flow. This may lead to episodes of chest pain, heart attacks, or strokes as the artery becomes blocked. The condition often develops slowly over many years and can affect multiple vessels.
Overweight – A condition where a person’s body weight is higher than what is considered healthy for their height, usually defined by a body‑mass index of 25 to 29.9 kg/m². Excess weight can cause the heart to work harder and may increase the amount of fatty tissue in blood vessels. As the extra weight persists, the risk of developing heart and blood‑vessel problems grows gradually.
Obesity – A chronic condition characterized by an excess amount of body fat, typically defined by a body‑mass index of 30 kg/m² or higher. The surplus fat can lead to inflammation and accumulation of plaque in arteries over time. This progressive buildup can worsen blood flow and increase the chance of heart‑related events as the condition continues.